AUTHOR=You Ran , Xu Qingyu , Wang Qi , Zhang Qingqiao , Zhou Weizhong , Cao Chi , Huang Xiangzhong , Ji Honghai , Lv Penghua , Jiang Hao , Lu You , Jin Yong , Li Yongjun , Cheng Long , Wang Weidong , Xu Hao , Zhu Xiaoli , Yin Guowen 

TITLE=Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.816198

DOI=10.3389/fonc.2022.816198

ISSN=2234-943X

ABSTRACT=Objective: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study aimed to evaluate the efficacy and safety of camrelizumab plus transarterial chemoembolization (TACE) in treating intermediate to advanced HCC patients.
Methods: This study consecutively enrolled 101 intermediate to advanced HCC patients. All patients received camrelizumab-based treatment within 30 days of the perioperative period of the TACE operation. The primary outcome was progression-free survival (PFS), and the secondary effects were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and AEs. 
Results: Detailly, the median PFS was 9.7 (95% confidence interval: 7.4-12.0) months with a 1-year PFS rate of 30.6%. Meanwhile, the median OS was not reached (NR) yet, with a 1-year OS rate of 61.9%. Besides, the CR, PR, SD and PD rates were 12.8%, 44.9%, 29.5% and 12.8%, respectively. The ORR and DCR were 57.7% and 87.2%, separately. More cycles of camrelizumab independently correlated with prolonged PFS (hazard ratio (HR): 0.415, P=0.002), while longer interval between camrelizumab administration and TACE independently associated with unfavorable PFS (HR: 1.873, P=0.032). The incidence of total AEs was 90.1%; Most AEs were grade 1 (20.8%), grade 2 (28.7%) and grade 3 (37.6%), while only 3 (3.0%) patients occurred grade 4 AEs.
Conclusion: Camrelizumab plus TACE regimen is effective and safe, indicating its potential to serve as a promising treatment choice for intermediate to advanced HCC patients.